Global research priorities in rheumatic fever and rheumatic heart disease

Annals of Pediatric Cardiology

Volumn 4, Issue 1, 2011, Pages 4-12

  Carapetis, Jonathan R ^a,b   Zühlke, Liesl J ^c  

^a MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^b WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

prevention; Rheumatic fever; rheumatic heart disease

Indexed keywords

ANTICOAGULANT AGENT; BENZATHINE PENICILLIN; NALTREXONE; STREPTOCOCCUS GROUP A VACCINE; STREPTOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ANTIBIOTIC THERAPY; ANTICOAGULANT THERAPY; ARTICLE; CARDITIS; CHRONIC DISEASE; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DISEASE REGISTRY; DRUG IMPLANT; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY; ECONOMIC ASPECT; EVIDENCE BASED PRACTICE; GENETIC SUSCEPTIBILITY; HEALTH PROGRAM; HEART SURGERY; HUMAN; IMMUNOPATHOGENESIS; INFECTION CONTROL; INFECTION PREVENTION; MEDICAL RESEARCH; PATHOGENESIS; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRIMARY MEDICAL CARE; PRIMARY PREVENTION; RHEUMATIC FEVER; RHEUMATIC HEART DISEASE; SCREENING TEST; SECONDARY PREVENTION; SKIN INFECTION;

EID: 79955390762     PISSN: 09742069     EISSN: 09745149     Source Type: Journal    
DOI: 10.4103/0974-2069.79616     Document Type: Article

References (48)

1. WHO Expert Consultation on Rheumatic Fever and Rheumatic Heart Disease (2001: Geneva Switzerland). Rheumatic fever and rheumatic heart disease: Report of a WHO Expert Consultation, Geneva, 29 October - 1 November 2001. WHO Technical Report Series; 923. Geneva: World Health Organization; 2004.
2. Rimoin AW, Hamza HS, Vince A, Kumar R, Walker CF, Chitale RA, et al. Evaluation of the WHO clinical decision rule for streptococcal pharyngitis. Arch Dis Child 2005;90:1066-70. (Pubitemid 41406616)
3. Carapetis JR, Steer AC, Mulholland EK. The current evidence for the burden of group A streptococcal diseases (WHO/FCH/CAH/05.07). Geneva: World Health Organization; 2004.
4. Carapetis JR. Group A streptococcal vaccine development: Current status and issues of relevance to less developed countries (WHO/FCH/CAH/05.09 and WHO/IVB/05.14). Geneva: World Health Organization; 2004.
5. Carapetis JR. A review of the technical basis for the current WHO approach to the control of conditions associated with group A streptococcal infections (WHO/ FCH/CAH/05.08). Geneva: World Health Organization; 2004.
6. Mayosi B, Robertson K, Volmink J, Adebo W, Akinyore K, Amoah A, et al. The Drakensberg declaration on the control of rheumatic fever and rheumatic heart disease in Africa. S Afr Med J 2006;96:246.
7. Colquhoun SM, Carapetis JR, Kado JH, Steer AC. Rheumatic heart disease and its control in the Pacific. Expert Rev Cardiovasc Ther 2009;7:1517-24.
8. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand. Diagnosis and management of acute rheumatic fever and rheumatic heart disease in Australia: An evidence-based review. Melbourne: National Heart Foundation of Australia; 2006.
9. Kumar R, Thakur JS, Aggarwal A, Ganguly NK. Compliance of secondary prophylaxis for controlling rheumatic fever and rheumatic heart disease in a rural area of northern India. Indian Heart J 1997;49:282-8.
10. Bach JF, Chalons S, Forier E, Elana G, Jouanelle J, Kayemba S, et al . 10-year educational programme aimed at rheumatic fever in two French Caribbean islands. Lancet 1996;347:644-8. (Pubitemid 26076130)
11. Wilson N. Rheumatic heart disease in indigenous populations-New Zealand experience. Heart Lung Circ 2010;19:282-8.
12. Tibazarwa KB, Volmink JA, Mayosi BM. Incidence of acute rheumatic fever in the world: A systematic review of population-based studies. Heart 2008;94:1534-40.
13. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis 2005;5:685-94. (Pubitemid 41505357)
14. Mincham CM, Mak DB, Plant AJ. The quality of management of rheumatic fever/heart disease in the Kimberly. Aust N Z J Public Health 2002;26:417-20. (Pubitemid 36167898)
15. Harrington Z, Thomas DP, Currie BJ, Bulkanhawuy J. Challenging perceptions of non-compliance with rheumatic fever prophylaxis in a remote Aboriginal community (mm ref 2769). Med J Aust 2006;184:514-7. (Pubitemid 43732940)
16. Gardner KL, Dowden M, Togni S, Bailie R. Understanding uptake of continuous quality improvement in Indigenous primary health care: Lessons from a multi-site case study of the Audit and Best Practice for Chronic Disease project. Implement Sci 2010;5:21.
17. Zaher S, Kassem A, Abou-Shleib H, El Khouly A, Madkour A, Kaplan E. Differences in serum penicillin concentrations following intramuscular injection of benzathine penicillin G (BPG) from different manufacturers. J Pharm Med 1992;2:17-23.
18. Stollerman GH, Rusoff JH. Prophylaxis against group A streptococcal infections in rheumatic fever patients; Use of new repository penicillin preparation. J Am Med Assoc 1952;150:1571-5.
19. Kassem AS, Zaher SR, Abou Shleib H, el-Kholy AG, Madkour AA, Kaplan EL. Rheumatic fever prophylaxis using benzathine penicillin G (BPG): Two- Week versus four-week regimens: Comparison of two brands of BPG. Pediatrics 1996;97:992-5.
20. Kaplan EL, Berrios X, Speth J, Siefferman T, Guzman B, Quesny F. Pharmacokinetics of benzathine penicillin G: Serum levels during the 28 days after intramuscular injection of 1,200,000 units. J Pediatr 1989;115:146-50. (Pubitemid 19177987)
21. Bass JW, Longfield JN, Jones RG, Hartmann RM. Serum levels of penicillin in basic trainees in the U.S. Army who received intramuscular penicillin G benzathine. Clin Infect Dis 1996;22:727-8. (Pubitemid 26286332)
22. Ngo HT, Arnold-Reed DE, Hansson RC, Tait RJ, Hulse GK. Blood naltrexone levels over time following naltrexone implant. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:23-8.
23. Nordet P, Lopez R, Duenas A, Sarmiento L. Prevention and control of rheumatic fever and rheumatic heart disease: The Cuban experience (1986-1996-2002). Cardiovasc J Afr 2008;19:135-40.
24. Michaud C, Rammohan R, Narula J. Cost-effectiveness analysis of intervention strategies for reduction of the burden of rheumatic heart disease. In: Narula J, Virmani R, Reddy KS, Tandon R, editors. Rheumatic fever. Washington DC: American Registry of Pathology; 1999. p. 485-97.
25. Michaud C, Gutierrez J, Cruz C, Pearson T. The World Bank health sector priorities review: Rheumatic heart disease. World Bank ,Washington, D C; 1991. p. 1-31.
26. Carapetis JR, Powers JR, Currie BJ. Outcomes of cardiac valve replacement for rheumatic heart disease in Aboriginal Australians. Asia Pac Heart J 2000;8:138-47.
27. Levine HJ, Pauker SG, Salzman EW. Antithrombotic therapy in valvular heart disease. Chest 1986;89:36S-45. (Pubitemid 16083096)
28. Salem DN, Stein PD, Al-Ahmad A, Bussey HI, Horstkotte D, Miller N, et al. Antithrombotic therapy in valvular heart disease-native and prosthetic: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:457S-82S. (Pubitemid 39297961)
29. Sanyal SK, Thapar MK, Ahmed SH, Hooja V, Tewari P. The initial attack of acute rheumatic fever during childhood in North India; A prospective study of the clinical profile. Circulation 1974;49:7-12.
30. Feinstein AR, Wood HF, Spagnuolo M, Taranta A, Jonas S, Kleinberg E, et al. Rheumatic Fever in Children and Adolescents. A Long-Term Epidemiologic Study of Subsequent Prophylaxis, Streptococcal Infections, and Clinical Sequelae. Vii. Cardiac Changes and Sequelae. Ann Intern Med 1964;60:87-123.
31. Paar JA, Berrios NM, Rose JD, Cáceres M, Peña R, Pérez W, et al. Prevalence of rheumatic heart disease in children and young adults in Nicaragua. Am J Cardiol 2010;105:1809-14.
32. Marijon E, Ou P, Celermajer DS, Ferreira B, Mocumbi AO, Jani D, et al. Prevalence of rheumatic heart disease detected by echocardiographic screening. N Engl J Med 2007;357:470-6. (Pubitemid 47204876)
33. Carapetis JR, Hardy M, Fakakovikaetau T, Taib R, Wilkinson L, Penny DJ, et al . Evaluation of a screening protocol using auscultation and portable echocardiography to detect asymptomatic rheumatic heart disease in Tongan schoolchildren. Nat Clin Pract Cardiovasc Med 2008;5:411-7. (Pubitemid 351935575)
34. Cherian T, Mulholland EK, Carlin JB, Ostensen H, Amin R, de Campo M, et al . Standardized interpretation of paediatric chest radiographs for the diagnosis of pneumonia in epidemiological studies. Bull World Health Organ 2005;83:353-9. (Pubitemid 40704864)
35. Jones TD. Diagnosis of rheumatic fever. JAMA 1944;126:481-4.
36. Heart Foundation of New Zealand and Cardiac Society of Australia and New Zealand. New Zealand Guidelines for Rheumatic Fever. 1. Diagnosis, management and secondary prevention. Auckland: Heart Foundation of New Zealand; 2006.
37. Mataika R, Carapetis JR, Kado J, Steer AC. Acute rheumatic fever: An important differential diagnosis of septic arthritis. J Trop Pediatr 2008;54:205-7. (Pubitemid 351827469)
38. Cilliers AM, Manyemba J, Saloojee H. Anti-inflammatory treatment for carditis in acute rheumatic fever. Cochrane Database Syst Rev 2003:CD003176.
39. Towers RJ, Bolm M, Currie BJ, Chhatwal GS, Fagan PK. Autoantigens identified by screening a human heart cDNA library with acute rheumatic fever sera. Ann N Y Acad Sci 2009;1173:83-91.
40. Engel ME Sr, Vogel J Adeyemo AA, Mayosi BM. Genetic contribution to rheumatic fever: A systematic review and meta-analysis of twin studies. [Presented at the 8th National Congress of the South African Heart Association, Sun City, 22-25 November 2007]. S Afr Med J 2007;97:1094.
41. Bryant PA, Robins-Browne R, Carapetis JR, Curtis N. Some of the people, some of the time: Susceptibility to acute rheumatic fever. Circulation 2009;119:742-53.
42. Karthikeyan G, Mayosi BM. Is primary prevention of rheumatic fever the missing link in the control of rheumatic heart disease in Africa? Circulation 2009;120:709-13.
43. Carapetis J, Steer A. Prevention of rheumatic fever. Pediatr Infect Dis J 2010;29:91-2; author reply 2.
44. Carapetis JR. Letter by Carapetis regarding article, "Is primary prevention of rheumatic fever the missing link in the control of rheumatic heart disease in Africa?" Circulation 2010;121:e384; author reply e5.
45. Lennon D, Stewart J, Farrell E, Palmer A, Mason H. School-based prevention of acute rheumatic fever: A group randomized trial in New Zealand. Pediatr Infect Dis J 2009;28:787-94.
46. Lennon D, Kerdemelidis M, Arroll B. Meta-analysis of trials of streptococcal throat treatment programs to prevent rheumatic fever. Pediatr Infect Dis J 2009;28:e259-64.
47. McDonald M, Currie BJ, Carapetis JR. Acute rheumatic fever: A chink in the chain that links the heart to the throat? Lancet Infect Dis 2004;4:240-5. (Pubitemid 38407307)
48. Lawrence G, Leafasia J, Sheridan J, Hills S, Wate J, Wate C, et al. Control of scabies, skin sores and haematuria in children in the Solomon Islands: Another role for ivermectin. Bull World Health Organ 2005;83:34-42.